

# Camillo Ribi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2608461/publications.pdf>

Version: 2024-02-01

34  
papers

2,137  
citations

567281

15  
h-index

395702

33  
g-index

39  
all docs

39  
docs citations

39  
times ranked

3622  
citing authors

#	ARTICLE	IF	CITATIONS
1	Behçet's-like adverse event or inaugural Behçet's disease after SARS-CoV-2 mRNA-1273 vaccination?. <i>Rheumatology</i> , 2022, 61, e112-e113.	1.9	24
2	Humoral Responses Against Variants of Concern by COVID-19 mRNA Vaccines in Immunocompromised Patients. <i>JAMA Oncology</i> , 2022, 8, e220446.	7.1	48
3	Phenotype of limited cutaneous systemic sclerosis patients with positive anti-topoisomerase I antibodies: data from the EUSTAR cohort. <i>Rheumatology</i> , 2022, 61, 4786-4796.	1.9	20
4	Long-term outcomes in corticosteroid-refractory Graves' orbitopathy treated with tocilizumab. <i>Clinical Endocrinology</i> , 2022, 97, 363-370.	2.4	7
5	Measurement of circulating CD21 <sup>+</sup> CD27 <sup>+</sup> B lymphocytes in SLE patients is associated with disease activity independently of conventional serological biomarkers. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
6	Restoration of NK Cell Cytotoxic Function With Elotuzumab and Daratumumab Promotes Elimination of Circulating Plasma Cells in Patients With SLE. <i>Frontiers in Immunology</i> , 2021, 12, 645478.	4.8	17
7	Successful Rapid Oral Desensitization to Ibrutinib in a Patient With Severe Immediate Hypersensitivity Reaction. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e745-e747.	0.4	1
8	Neuro-psychiatric manifestations in patients with systemic lupus erythematosus: A systematic review and results from the Swiss lupus cohort study. <i>Lupus</i> , 2021, 30, 1565-1576.	1.6	10
9	Variants Affecting the C-Terminal Tail of UINC93B1 Are Not a Common Risk Factor for Systemic Lupus Erythematosus. <i>Genes</i> , 2021, 12, 1268.	2.4	0
10	Autoimmune Hemolytic Anemia and Pulmonary Embolism: An Association to Consider. <i>TH Open</i> , 2021, 05, e8-e13.	1.4	13
11	Predictive factors of severe infections in patients with systemic necrotizing vasculitides: data from 733 patients enrolled in five randomized controlled trials of the French Vasculitis Study Group. <i>Rheumatology</i> , 2020, 59, 2250-2257.	1.9	13
12	Risk of malignancy in patients treated for systemic necrotising vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 431-433.	0.9	7
13	Impact of COVID-19 pandemic on SLE: beyond the risk of infection. <i>Lupus Science and Medicine</i> , 2020, 7, e000408.	2.7	22
14	ANCA-associated life-threatening systemic vasculitis after alemtuzumab treatment for multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1599-1602.	3.0	8
15	Autoantibody Signature in Cardiac Arrest. <i>Circulation</i> , 2020, 141, 1764-1774.	1.6	16
16	Anti-apolipoprotein A-1 autoantibodies correlate with disease activity in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 59, 534-544.	1.9	3
17	Successful desensitization to pomalidomide in a patient with POEMS syndrome with delayed-type hypersensitivity to immunomodulatory imid drugs. <i>Leukemia and Lymphoma</i> , 2019, 60, 3087-3089.	1.3	3
18	Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 563-580.	27.6	1,235

#	ARTICLE	IF	CITATIONS
19	The Fatigue Assessment Scale as a simple and reliable tool in systemic lupus erythematosus: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 80.	3.5	16
20	Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2019, 71, 1553-1570.	5.6	75
21	Anti-C1q Antibodies as Occurring in Systemic Lupus Erythematosus Could Be Induced by an Epstein-Barr Virus-Derived Antigenic Site. <i>Frontiers in Immunology</i> , 2019, 10, 2619.	4.8	22
22	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities. <i>Lancet Oncology</i> , The, 2019, 20, e54-e64.	10.7	149
23	Association of antibodies against myelin and neuronal antigens with neuroinflammation in systemic lupus erythematosus. <i>Rheumatology</i> , 2019, 58, 908-913.	1.9	19
24	Treatment of chronic non-infectious uveitis and scleritis. <i>Swiss Medical Weekly</i> , 2019, 149, w20025.	1.6	9
25	Prevalence, persistence and clinical correlations of classic and novel antiphospholipid antibodies in systemic lupus erythematosus. <i>Rheumatology</i> , 2018, 57, 1350-1357.	1.9	28
26	Antibodies to <i>Chlamydia trachomatis</i> and reproductive health issues in women with SLE: a case-control study. <i>Lupus Science and Medicine</i> , 2018, 5, e000293.	2.7	0
27	Autoantibodies Against Albumin in Patients With Systemic Lupus Erythematosus. <i>Frontiers in Immunology</i> , 2018, 9, 2090.	4.8	16
28	Eosinophilic esophagitis: latest insights from diagnosis to therapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1434, 84-93.	3.8	20
29	Impact of disease activity on health-related quality of life in systemic lupus erythematosus - a cross-sectional analysis of the Swiss Systemic Lupus Erythematosus Cohort Study (SSCS). <i>BMC Immunology</i> , 2017, 18, 17.	2.2	42
30	Infections Associated with Immunobiologics. , 2017, , 796-804.e2.		0
31	Pneumococcal polysaccharide vaccination in adults undergoing immunosuppressive treatment for inflammatory diseases - a longitudinal study. <i>Arthritis Research and Therapy</i> , 2015, 17, 151.	3.5	60
32	Vaccination recommendations for adult patients with autoimmune inflammatory rheumatic diseases. <i>Swiss Medical Weekly</i> , 2015, 145, w14159.	1.6	65
33	The Swiss Systemic lupus erythematosus Cohort Study (SSCS) - cross-sectional analysis of clinical characteristics and treatments across different medical disciplines in Switzerland. <i>Swiss Medical Weekly</i> , 2014, 144, w13990.	1.6	31
34	Impact of synthetic and biologic disease-modifying antirheumatic drugs on antibody responses to the AS03-adjuvanted pandemic influenza vaccine: A prospective, open-label, parallel-cohort, single-center study. <i>Arthritis and Rheumatism</i> , 2011, 63, 1486-1496.	6.7	119